Publication Name	World Journal of Meta-Analysis
Manuscript ID	49946
Country	Greece

Received	2019-06-27 00:24
Peer-Review Started	2019-06-29 04:07
To Make the First Decision	2019-08-02 07:03
Return for Revision	2019-08-02 09:08
Revised	2019-08-07 14:42
Second Decision	2019-08-16 12:47
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2019-08-20 03:05
Articles in Press	2019-08-20 03:05
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2019-08-27 07:38
Publish the Manuscript Online	2019-09-03 07:56

ISSN	2308-3840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Review
Article Title	Antidiabetic agents in patients with hepatic impairment
Manuscript Source	Invited Manuscript
All Author List	Athanasia Papazafeiropoulou and Αndreas Μelidonis
Funding Agency and Grant Number
Corresponding Author	Athanasia Papazafeiropoulou, MD, MSc, PhD, Attending Doctor, Research Scientist, 1st Department of Internal Medicine and Diabetes Center, Tzaneio General Hospital of Piraeus, 1 Zanni and Afentouli Street, Athens 18536, Greece. pathan@ath.forthnet.gr
Key Words	Hepatic impairment; Type 2 diabetes mellitus; Pharmacokinetics; Antidiabetic drugs; ;
Core Tip	Most of the antidiabetic agents, with the exception of insulin, need dosage titration due to alterations to their pharmacokinetics in patients with chronic liver disease (CLD). For well-established antidiabetic treatments, like metformin and sulfonylureas there are studies regarding their dosage chance in these patients. However, despite the growing problem of management of diabetes in patients with CLD the existing literature data, especially on newer antidiabetic agents, are limited and, furthermore, no direct guidelines exist. Therefore, in the present review article we try to summarize the existing literature data regarding management of diabetes in patients with CLD.
Publish Date	2019-09-03 07:56
Citation	Pazafiropoulou A, Melidonis A. Antidiabetic agents in patients with hepatic impairment. World J Meta-Anal 2019; 7(8): 380-388
URL	https://www.wjgnet.com/2308-3840/full/v7/i8/380.htm
DOI	https://dx.doi.org/10.13105/wjma.v7.i8.380

Full Article (PDF)	WJMA-7-380.pdf
Full Article (Word)	WJMA-7-380.docx
Manuscript File	49946-Review.docx
Answering Reviewers	49946-Answering reviewers.pdf
Audio Core Tip	49946-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	49946-Conflict-of-interest statement.pdf
Copyright License Agreement	49946-Copyright license agreement.pdf
Peer-review Report	49946-Peer-review(s).pdf
Scientific Misconduct Check	49946-Scientific misconduct check.pdf
Scientific Editor Work List	49946-Scientific editor work list.pdf